Iacopo Olivotto
Overview
Explore the profile of Iacopo Olivotto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
461
Citations
9783
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davis B, Volk H, Nguyen O, Kamna D, Chen H, Barriales-Villa R, et al.
J Am Heart Assoc
. 2025 Mar;
:e038758.
PMID: 40055855
Background: Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the pharmacologic...
2.
3.
Bonanni F, Servoli C, Spaziani G, Bennati E, Di Filippo C, Cirri G, et al.
Diagnostics (Basel)
. 2025 Feb;
15(4).
PMID: 40002632
Early surgery and improved medical care have led to the increased survival of neonates with congenital heart disease (CHD), who now commonly reach adulthood. Among adults with CHD, a growing...
4.
Bertero E, Canepa M, Pieroni M, Olivotto I
G Ital Cardiol (Rome)
. 2025 Feb;
26(3):185-194.
PMID: 39998348
Therapeutic options for the treatment of hypertrophic obstructive cardiomyopathy have recently expanded with the introduction of myosin inhibitors, mavacamten and aficamten, which demonstrated a remarkable effect on functional capacity and...
5.
Parikh V, Day S, Lakdawala N, Adler E, Olivotto I, Seidman C, et al.
Cell
. 2025 Feb;
188(4):901-918.
PMID: 39983674
Cardiomyopathies are primary disorders of the heart muscle. Three key phenotypes have been defined, based on morphology and arrhythmia burden: hypertrophic cardiomyopathy (HCM), with thickened heart muscle and diastolic dysfunction;...
6.
Tadros R, Zheng S, Grace C, Jorda P, Francis C, West D, et al.
Nat Genet
. 2025 Feb;
57(3):530-538.
PMID: 39966646
Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality with both monogenic and polygenic components. Here, we report results from a large genome-wide association study and multitrait analysis...
7.
Maurizi N, Monda E, Biagini E, Field E, Passantino S, Dall Aglio G, et al.
Eur Heart J
. 2025 Feb;
PMID: 39928417
Background And Aims: The European Society of Cardiology guidelines recommend a systematic search for diagnostic clues or 'red flags' (RFs) in patients with hypertrophic cardiomyopathy (HCM) to better tailor disease...
8.
Desai M, Nissen S, Abraham T, Olivotto I, Garcia-Pavia P, Lopes R, et al.
JACC Heart Fail
. 2025 Feb;
13(2):358-370.
PMID: 39909647
There are no approved therapies for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The authors describe the baseline characteristics of ODYSSEY-HCM (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy), a...
9.
Butters A, Arnott C, Sweeting J, Claggett B, Cuomo A, Cuomo A, et al.
Circ Genom Precis Med
. 2025 Jan;
18(1):e004641.
PMID: 39851041
Background: Females with hypertrophic cardiomyopathy present at a more advanced stage of the disease and have a higher risk of heart failure and death. The factors behind these differences are...
10.
Charman S, Okwose N, Groenewegen A, Del Franco A, Tafelmeier M, Preveden A, et al.
BMJ Open
. 2025 Jan;
15(1):e091793.
PMID: 39773784
Introduction: Heart failure (HF) is a complex clinical syndrome. Accurate risk stratification and early diagnosis of HF are challenging as its signs and symptoms are non-specific. We propose to address...